John M. Gay - 10 Apr 2026 Form 3 Insider Report for Pelthos Therapeutics Inc. (PTHS)

Reporting relationship: Chief Financial Officer
Issuer ticker: PTHS
Reported as of: 10 Apr 2026
Net transaction value: $0
SEC form: 3
Accepted by SEC: 20 Apr 2026, 17:00:41 UTC
Prior SEC filing: 08 Jun 2023
Source filing: View source filing
Reporting owner signature: /s/ John M. Gay

Key filing fact

John M. Gay filed Form 3 for Pelthos Therapeutics Inc. (PTHS) on 20 Apr 2026.

Key facts

This page summarizes John M. Gay's Form 3 filing for Pelthos Therapeutics Inc. (PTHS).
0 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 20 Apr 2026, 17:00.

Change

Previous filing in this sequence was filed on 08 Jun 2023.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Official SEC source

Ownership activity is grounded in SEC Form 3 disclosures.

View source filing

Reporting Owners (1)

CIK 0001765684 Primary reporting owner

GAY JOHN M.

Relationship: Chief Financial Officer
Address: C/O PELTHOS THERAPEUTICS INC., 4020 STIRRUP CREEK DRIVE, SUITE 110, DURHAM
Signature: /s/ John M. Gay
Signature date: 20 Apr 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

PTHS holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 30,518
Date: 10 Apr 2026
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

PTHS holding Derivative

Stock Option

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date: 10 Apr 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 93,000
Exercise price: $13.50
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Represents 30,518 shares of common stock, par value $0.0001 per share ("Common Stock") of Pelthos Therapeutics Inc. (the "Issuer"), issuable upon settlement of restricted stock units of the Issuer ("RSUs") granted to the reporting person on July 2, 2025 pursuant to the Issuer's 2023 Equity Incentive Plan, as amended from time to time (the "2023 Plan"), each of which represents the right to receive one (1) share of Common Stock, subject to the vesting terms of such RSUs, and may be settled solely in shares of Common Stock. The RSUs were received as compensation for the reporting person's service as an officer of the Issuer pursuant to the 2023 Plan. The RSUs vest as follows: the initial one-third (1/3) of such shares vests on July 2, 2026, and the remainder vesting in equal installments on a quarterly basis thereafter over a period of two years, so long as the reporting person remains in the service of the Issuer on each such vesting date.

Footnote F2

On July 2, 2025, the reporting person was granted stock options to purchase 93,000 shares of Common Stock at an exercise price of $13.50 per share, with the initial one third (1/3) of such shares vesting on July 2, 2026, and in equal installments on a quarterly basis thereafter over a period of two (2) years, so long as the reporting person remains in the service of the Issuer on each such vesting date.